-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing, November 4, 2021/PRNewswire/ - Today, Genetron Health (Nasdaq: GTH) announced the acquisition of its self-developed human 825 gene mutation detection kit (combined probe-anchored polymerization sequencing method) EU CE qualification (registration number: DE/CA20/01-IVD-Luxuslebenswelt-334/21)
The kit can be equipped with Genetron's high-throughput NGS sequencing platform GENETRON S2000 (National Instruments Note 20203220081), providing an integrated large panel solution for clinical use
Human 825 gene mutation detection kit is based on "hybrid capture" and NGS sequencing technology, combined with multiple cancer solid tumor gene mutation regions and genetic variant gene loci, covering WHO, NCCN, ESMO and other authoritative guidelines and expert consensus recommendations to detect genes, As well as the cutting-edge academic achievements and major discoveries of related genes in solid tumors, comprehensive molecular information can be obtained through a single test, which can comprehensively evaluate targeted therapy and immunotherapy (TMB evaluation, MSI, immune efficacy-related genes) programs, and accurately guide tumor patients’ Individualized diagnosis and treatment, and simultaneous genetic susceptibility risk screening
Genetron Health Co.
About CE
CE Marking (CE Marking) is a product safety mark that must be carried when some products are listed in some European countries in accordance with regulatory requirements
About Genetron
Genetron Health (Nasdaq: GTH) is a global cutting-edge cancer precision medicine company, focusing on cancer genomics research and applications, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities
Safe Harbor Statement
This press release contains Genetron Health's future expectations, plans and forward-looking statements, which are subject to corresponding risks and uncertainties, which may cause actual results to differ from the expectations described in the forward-looking statements
Source: Genetron Health
